GSK (LON:GSK) Reaches New 52-Week High – Should You Buy?
by Renee Jackson · The Cerbat GemGSK plc (LON:GSK – Get Free Report)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as GBX 1,905.50 and last traded at GBX 1,847.50, with a volume of 11248268 shares changing hands. The stock had previously closed at GBX 1,820.50.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on GSK shares. Jefferies Financial Group boosted their price target on GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a research note on Monday, November 3rd. JPMorgan Chase & Co. upped their target price on GSK from GBX 1,400 to GBX 1,500 and gave the company an “underweight” rating in a research report on Friday, November 7th. Berenberg Bank increased their price target on shares of GSK from GBX 1,600 to GBX 1,660 and gave the stock a “hold” rating in a report on Monday, November 24th. Finally, Shore Capital restated a “buy” rating and set a GBX 2,100 price objective on shares of GSK in a research note on Monday, October 20th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, GSK currently has an average rating of “Hold” and a consensus target price of GBX 1,762.
Get Our Latest Analysis on GSK
GSK Stock Performance
The business’s 50-day simple moving average is GBX 1,798.51 and its two-hundred day simple moving average is GBX 1,590.26. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm has a market cap of £74.60 billion, a price-to-earnings ratio of 13.89, a P/E/G ratio of 1.24 and a beta of 0.31.
GSK (LON:GSK – Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. As a group, sell-side analysts expect that GSK plc will post 175.980975 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, insider Wendy Becker bought 441 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were acquired at an average price of GBX 1,809 per share, for a total transaction of £7,977.69. Also, insider Jonathan Symonds purchased 1,650 shares of GSK stock in a transaction that occurred on Monday, December 22nd. The shares were bought at an average price of GBX 1,810 per share, with a total value of £29,865. Insiders have bought a total of 2,106 shares of company stock worth $3,808,884 in the last quarter. Insiders own 0.20% of the company’s stock.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.